Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 28, 2002
Business Overview: The Company operates two primary segments: Healthcare Distribution (dental, medical, and international markets) and Technology (practice management software and value-added services). The Company distributes healthcare products and services to office-based practitioners globally.
Key Financial Metrics (Nine Months Ended Sept 28, 2002)
| Metric | 2002 (9 Months) | 2001 (9 Months) | Change |
|---|---|---|---|
| Net Sales | $2,077.6 million | $1,860.0 million | +11.7% |
| Gross Profit | $587.3 million | $505.1 million | +16.3% |
| Gross Margin | 28.3% | 27.2% | +1.1% |
| Operating Income | $146.5 million | $104.7 million | +40.0% |
| Net Income | $87.0 million | $60.2 million | +44.5% |
| Diluted EPS | $1.94 | $1.39 | +39.6% |
| Operating Cash Flow | $65.7 million | $79.1 million | -17.0% |
| Cash & Equivalents | $149.3 million | $107.9 million (end of period) | N/A |
| Long-Term Debt | $242.1 million | $242.2 million | Flat |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased $217.6 million, driven primarily by the Healthcare Distribution segment (+11.6%). The Medical business saw the strongest growth (+16.3%), partly due to earlier influenza vaccine shipments. The Technology segment grew 13.8%.
- Profitability Expansion: Operating income surged 40% to $146.5 million. This was significantly aided by the adoption of FAS 142, which eliminated goodwill amortization expense. Gross margins improved across both segments due to sales mix changes and purchasing efficiencies.
- Cash Flow Dynamics: Operating cash flow decreased by $13.4 million compared to the prior year. This decline was primarily due to a $43.2 million net increase in working capital, specifically a $49.0 million rise in accounts receivable and an $18.1 million increase in inventory.
- Investing Activities: Net cash used in investing activities increased significantly to $124.5 million (from $32.9 million), driven by $50.3 million in purchases of marketable securities, $36.3 million in capital expenditures, and $34.9 million in acquisition-related payments.
Guidance, Outlook, and Risks
- Seasonality: Management notes that sales and profits are typically higher in the fourth quarter due to year-end promotions and purchasing patterns, while the first quarter is generally lower.
- Capital Requirements: The Company anticipates future increases in working capital needs due to sales growth and inventory forward buy-ins. It expects to invest over $50.0 million in capital projects for the remainder of the fiscal year.
- Liquidity: The Company maintains a $200.0 million revolving credit facility (unused as of Sept 28, 2002) and $149.3 million in cash equivalents. Management believes current resources are sufficient for foreseeable needs.
- Legal Proceedings:
- Product Liability: The Company is a defendant in approximately 68 cases, including 49 involving latex glove allergies and 9 involving "Phen/fen" drugs. The Company expects indemnification from manufacturers where applicable.
- Class Action (Software): A Texas Supreme Court ruling in October 2002 reversed a lower court's certification of a class action regarding practice management software. The case was remanded, and the potential range of damages remains undetermined.
- Class Action (Vaccine): A New Jersey lawsuit alleges breach of contract regarding vaccine sales. Damages are unspecified, and the Company intends to vigorously defend the claim.
- Market Risks: Risks include foreign currency fluctuations, consolidation of healthcare practitioners, healthcare reform, and competitive pressures from e-commerce solutions.
Investor Verification Checklist
- Working Capital Efficiency: Verify the sustainability of the $49 million increase in accounts receivable and the impact on future cash conversion cycles.
- Goodwill Amortization Impact: Confirm the extent to which the 40% increase in operating income is attributable to the elimination of goodwill amortization (FAS 142) versus organic operational improvements.
- Legal Exposure: Monitor the status of the remanded software class action and the indemnification status of the latex glove and "Phen/fen" liability cases.
- Inventory Levels: Assess the $18.1 million increase in inventory to ensure it aligns with sales growth and does not indicate obsolescence risks.
- Debt Covenants: Review the terms of the $200 million credit facility and the $230 million in senior notes to ensure compliance with financial covenants given the current debt levels.